Clinical trial · no report yet · Phase 1/Phase 2
NCT06128551
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NCT06128551 ↗
- Recruiting
- Revolution Medicines, Inc.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase 1b/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients With Advanced KRAS G12C-Mutated Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer; Pancreatic Ductal Adenocarcinoma
- Interventions
- Elironrasib; Daraxonrasib
- Arms
- Elironrasib Monotherapy · Experimental
- Daraxonrasib Monotherapy · Experimental
- Daraxonrasib + Elironrasib Combination · Experimental
- Enrollment
- 534 (estimated)
- Primary outcomes
- Number of patients with adverse events (AEs) in Phase 1b
- Changes in vital signs in Phase 1b
- Changes in clinical laboratory test values in Phase 1b
- Dose Limiting Toxicities in Phase 1b
- Changes in ECGs in Phase 1b
- Overall Response Rate (ORR) in Phase 2
- Sponsor
- Revolution Medicines, Inc.
- Start
- Nov 14, 2023
- Primary completion
- Dec 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06128551 · updated Sep 22, 2026
Publications
linked from the registry- Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, Marquez A, Liu Y, Freilich R, Aay N, Wang Y, Jiang L, Jiang J, Wang Z, Flagella M, Wildes D, Smith JAM, Singh M, Wang Z, Gill AL, Koltun ES. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J Med Chem. 2025 Mar 27;68(6):6064-6083. doi: 10.1021/acs.jmedchem.4c02314. Epub 2025 Mar 8. PubMed 40056080